Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly Focuses On China R&D Instead Of M&A

This article was originally published in PharmAsia News

Executive Summary

U.S.-based Eli Lilly is counting on China as the best example of fast-growing health care markets. It is betting on that belief by focusing on research and development in the country instead of making mergers and acquisitions, a practice of many of its competitors. Global CEO John Lechleiter said the company intends to take advantage of the rapid growth in emerging markets, particularly China where the huge population is aging and becoming more wealthy. Lilly plans to launch 15 drugs in China over the next five years and invest 20 percent of revenue in R&D, about five percent more than typical of other pharmaceuticals. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts